HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Michel E. Ribet Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lafitte, J. J. Articles by Brichet, A. H. Search for Related Content PubMed PubMed Citation Articles by Lafitte, J. J. Articles by Brichet, A. H.

Ann Thorac Surg 1996;62:830-834
© 1996 The Society of Thoracic Surgeons

---

Original Articles: General Thoracic

Postresection Irradiation for T2 N0 M0 Non–Small Cell Carcinoma: A Prospective, Randomized Study

Department of Pneumology, , Unit of Thoracic Surgery, Unit of Radiotherapy (Centre Oscar Lambret), and Laboratory of Pathology, Hôpital Calmette, Centre Hospitalier Régional Universitaire, Lille, France

Accepted for publication April 20, 1996.

Background. Stage I nonirradiated T2 N0 non–small cell lung carcinoma has a postoperative prognosis not very different from stage II irradiated T1 N1 carcinoma. The hypothesis was that more locoregional malignant sites are overlooked in T2 N0 M0 than in T1 N0 M0 tumors, considering the better prognosis of this last group, and that T2 N0 cancer might benefit from postresection irradiation.

Methods. From 1985 to 1991, 163 non–small cell lung carcinomas were classified T2 N0 M0 and randomized for irradiation or nonirradiation after operation. After revision of all the cases, 132 were included in this study: 60 were irradiated and 72 were not irradiated. All were followed up. The study was closed in October 1995. Statistical analysis was then performed considering volume, location, cell type, survival, and recurrence in the two groups.

Results. One hundred thirteen patients were followed up during a minimum of 5 years: the survival was 44.2%. There was no significant difference considering cell type or irradiation. There was no recurrence-free survivor beyond 5 years with a tumor invading the visceral pleura. At the close of the study (follow up, 4 years 3 months to 10 years 1 month), 49 of 132 patients were alive. The median survival was 3 years 11 months. Fifty-nine patients had died of local (21) or distant (40) recurrences (2 patients had both local and distant recurrence). There was again no significant difference considering cell type or irradiation, either in the survival or in the mode of recurrence.

Conclusions. Stage I T2 N0 M0 non–small cell lung carcinoma tends to manifest distant metastasis. Prospective studies of stratified systemic adjuvant therapy should improve the present moderate result of radical resection in this group of tumors.

This article has been cited by other articles:

				D. R. Jones, T. M. Daniel, C. E. Denlinger, B. K. Rundall, M. E. Smolkin, and M. R. Wick Stage IB Nonsmall Cell Lung Cancers: Are They All the Same? Ann. Thorac. Surg., June 1, 2006; 81(6): 1958 - 1962. [Abstract] [Full Text] [PDF]

				E. D. Bernstein, S. M. Herbert, and N. H. Hanna Chemotherapy and Radiotherapy in the Treatment of Resectable Non-Small-Cell Lung Cancer Ann. Surg. Oncol., March 1, 2006; 13(3): 291 - 301. [Abstract] [Full Text] [PDF]

				J. A. Bogart and J. N. Aronowitz Localized Non-Small Cell Lung Cancer: Adjuvant Radiotherapy in the Era of Effective Systemic Therapy Clin. Cancer Res., July 1, 2005; 11(13): 5004s - 5010s. [Abstract] [Full Text] [PDF]

				J. D. Bradley, R. Paulus, M. V. Graham, D. S. Ettinger, D. W. Johnstone, M. V. Pilepich, M. Machtay, R. Komaki, J. Atkins, and W. J. Curran Phase II Trial of Postoperative Adjuvant Paclitaxel/Carboplatin and Thoracic Radiotherapy in Resected Stage II and IIIA Non-Small-Cell Lung Cancer: Promising Long-Term Results of the Radiation Therapy Oncology Group--RTOG 9705 J. Clin. Oncol., May 20, 2005; 23(15): 3480 - 3487. [Abstract] [Full Text] [PDF]

				A. Iwasaki, T. Shirakusa, S. Enatsu, S. Maekawa, Y. Yoshinaga, S. Yoneda, and S. Hoshino Is T2 non-small cell lung cancer located in left lower lobe appropriate to upstage? Interactive CardioVascular and Thoracic Surgery, April 1, 2005; 4(2): 126 - 129. [Abstract] [Full Text] [PDF]

				A. Spira and D. S. Ettinger Multidisciplinary Management of Lung Cancer N. Engl. J. Med., January 22, 2004; 350(4): 379 - 392. [Full Text] [PDF]

				P. Granone, L. Trodella, S. Margaritora, A. Cesario, G. M. Corbo, G. Mantini, M. Balducci, and G. Fumagalli Radiotherapy versus follow-up in the treatment of pathological stage Ia and Ib non-small cell lung cancer. Early stopped analysis of a randomized controlled study Eur. J. Cardiothorac. Surg., October 1, 2000; 18(4): 418 - 424. [Abstract] [Full Text] [PDF]

				H. Wagner Jr Postoperative Adjuvant Therapy for Patients With Resected Non-Small Cell Lung Cancer: Still Controversial After all These Years Chest, April 1, 2000; 117(4_suppl_1): 110S - 118S. [Abstract] [Full Text] [PDF]

				J. H. Lee, M. Machtay, L. R. Kaiser, J. S. Friedberg, S. M. Hahn, M. G. McKenna, and W. G. McKenna Non-Small Cell Lung Cancer: Prognostic Factors in Patients Treated with Surgery and Postoperative Radiation Therapy Radiology, December 1, 1999; 213(3): 845 - 852. [Abstract] [Full Text]